Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $23.25 USD
Change Today +0.33 / 1.44%
Volume 346.1K
FGEN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

fibrogen inc (FGEN) Snapshot

Open
$22.88
Previous Close
$22.92
Day High
$24.07
Day Low
$22.84
52 Week High
01/6/15 - $40.59
52 Week Low
06/2/15 - $16.95
Market Cap
1.4B
Average Volume 10 Days
396.9K
EPS TTM
--
Shares Outstanding
59.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FIBROGEN INC (FGEN)

Related News

No related news articles were found.

fibrogen inc (FGEN) Related Businessweek News

No Related Businessweek News Found

fibrogen inc (FGEN) Details

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing roxadustat, or FG-4592, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; FG-3019, a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. The company also has a PHD1 inhibitor program, FG-8205 that is in preclinical evaluation for use as a cardioprotective agent to prevent the onset of heart failure following a heart attack; and FG-6874, an another novel HIF-PH inhibitor that has completed Phase I single dose and multiple dose studies for hematopoietic stem cell mobilization and certain other indications. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

348 Employees
Last Reported Date: 03/26/15
Founded in 1993

fibrogen inc (FGEN) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $736.6K
Chief Medical Officer
Total Annual Compensation: $443.5K
Vice President of Clinical Development
Total Annual Compensation: $428.7K
Compensation as of Fiscal Year 2014.

fibrogen inc (FGEN) Key Developments

FibroGen, Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 02:00 PM

FibroGen, Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 02:00 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Thomas B. Neff, Founder, Chairman and Chief Executive Officer.

FibroGen, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015

FibroGen, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2015. For the quarter, total revenue was $16,298,000, loss from operations was $44,723,000, loss before income taxes was $46,638,000 and net loss was $46,367,000 or $0.78 per basic and diluted share against total revenue of $17,876,000, loss from operations of $14,206,000, loss before income taxes of $16,240,000 and net loss of $16,240,000 or $1.23 per basic and diluted share for the same period a year ago.

FibroGen, Inc., Annual General Meeting, Jun 03, 2015

FibroGen, Inc., Annual General Meeting, Jun 03, 2015., at 11:00 Pacific Standard Time. Location: InterContinental Hotel. Agenda: To elect nominees, Thomas B. Neff, Miguel Madero and James A. Schoeneck, to Board of Directors to hold office until the 2018 Annual Meeting of Stockholders; to ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the company for its year ending December 31, 2015; and to conduct any other business properly brought before the meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FGEN:US $23.25 USD +0.33

FGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FGEN.
View Industry Companies
 

Industry Analysis

FGEN

Industry Average

Valuation FGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.0x
Price/Book 7.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FIBROGEN INC, please visit www.fibrogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.